Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 8/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acefylline SCHEMBL18191994 | 0.92 | ADORA2B (1.00) | ADORA2BSMN1; SMN2MEN1KMT2ALMNA | |
| Acefylline SCHEMBL308514 | 0.92 | ADORA2B (1.00) | ADORA2BSMN1; SMN2MEN1KMT2ALMNA | |
| Acefylline SCHEMBL8402147 | 0.90 | ADORA2B (0.97) | ADORA2BSMN1; SMN2MEN1KMT2ALMNA | |
| Acefylline SCHEMBL1173152 | 0.86 | ADORA2B (0.89) | ADORA2BSMN1; SMN2MEN1KMT2ALMNA | |
| Acefylline SCHEMBL356114 | 0.84 | ADORA2B (0.85) | ADORA2BSMN1; SMN2MEN1KMT2ALMNA | |
| Acefylline SCHEMBL5493561 | 0.84 | ADORA2B (0.85) | ADORA2BSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL18526741 | 0.83 | SMN1; SMN2 (0.65) | ADORA2BSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL11531219 | 0.80 | ADORA2B (0.78) | ADORA2BSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL17163939 | 0.80 | ADORA2B (0.78) | ADORA2BSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL10178116 | 0.80 | PDE4A (0.81) | ADORA2BPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134410-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2021-03-10 | — | — | EP | disclosed |
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3134410-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | Hydra Biosciences, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | MERCK & CO., INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | MERCK & CO., INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2015164643-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPA1, TRPV1, TRPV2 | ADORA2B 161/4885SMN1; SMN2 713/4885MEN1 2983/4885 |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPA1, TRPV1, TRPV2 | ADORA2B 161/4885SMN1; SMN2 713/4885MEN1 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.